BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) CFO Aaron Rosenberg sold 631 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $257.74, for a total value of $162,633.94. Following the transaction, the chief financial officer owned 397,891 shares of the company’s stock, valued at approximately $102,552,426.34. This represents a 0.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
BeOne Medicines Stock Performance
Shares of NASDAQ ONC traded up $3.72 during midday trading on Monday, hitting $268.20. 351,440 shares of the company’s stock were exchanged, compared to its average volume of 258,341. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. The stock’s 50 day moving average price is $298.56 and its 200-day moving average price is $314.03. The firm has a market cap of $29.43 billion, a P/E ratio of 60.00 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $239.25 and a twelve month high of $385.22.
BeOne Medicines (NASDAQ:ONC – Get Free Report) last issued its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. The business had revenue of $1.51 billion during the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. Equities research analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current year.
Analyst Ratings Changes
Check Out Our Latest Report on BeOne Medicines
Hedge Funds Weigh In On BeOne Medicines
Several institutional investors and hedge funds have recently modified their holdings of ONC. Cetera Investment Advisers purchased a new position in shares of BeOne Medicines during the 2nd quarter valued at $455,000. Rhumbline Advisers bought a new stake in BeOne Medicines in the second quarter worth $275,000. Arrowstreet Capital Limited Partnership bought a new stake in BeOne Medicines in the second quarter worth $505,000. Invesco Ltd. acquired a new position in BeOne Medicines during the 2nd quarter worth $422,000. Finally, EverSource Wealth Advisors LLC acquired a new position in BeOne Medicines during the 2nd quarter worth $68,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.
BeOne Medicines Company Profile
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Read More
- Five stocks we like better than BeOne Medicines
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
